Drug Profile
MIV 160
Alternative Names: MIV-160Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Medivir AB
- Developer Beijing Mefuvir Medicinal Technology
- Class Antivirals
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended HIV infections
- No development reported HIV infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in China (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in China (Topical)
- 21 Aug 2007 Medivir has transferred the licensing rights of MIV 160 from Guangdong Lantai Viewland Pharmaceutical to Beijing Mefuvir Medicinal Technology